Biotechnology Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics to Participate in March Investor Conferences – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics to Announce Fourth Quarter Results on February 27, 2024 – Cytokinetics (NASDAQ:CYTK) Read more
Biotechnology Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference – Cytokinetics (NASDAQ:CYTK) Read more